The relationship between FDG PET/CT imaging characteristics and egfr gene mutations in patients with stage IV non-small cell lung cancer

Abstract

Aim: To evaluate the relationship between FDG PET/CT imaging characteristics and EGFR mutation status in patients with stage IV non-small cell lung cancer.

Subjects and research method: 108 patients with stage IV non-small cell lung cancer underwent FDG PET/CT scan, EGFR test before treatment from January 2018 to November 2020.

Result: The mean age was 62.1±9.2 (37 - 83), male (61.1%) female (38.9%), history of smoking (39.8%), stage IVa (31.5%) and stage IVb (68.5). 52.8% of the patients had EGFR mutation, in which exon 19 and exon 21 mutations are the highest with the rate of 31.5% and 18.5%. 48.1% of the patients received chemotherapy, 35.2% of patients on target treatment TKI Gender, smoking history, pSUVmax, tumor size are four independent predictors of EGFR gene mutation with OR 0.19, respectively (95% CI: 0.08-0.45; p<0.001);0.347 (95CI: 0,156-0,770; p=0.009); 0,0.805 (95% CI: 0.722-0.899; p<0.001) and 0.95 (95% CI: 0.911-0.993; p=0.022).

Conclusion: FDG PET/CT is valuable for predicting EGFR mutation levels in patients with non-small cell lung carcinoma.